$TGTX

TG Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$4.31 β–Ό-2.045%

Extented Hours

VOLUME

2,658,582

DAY RANGE

4.24 - 4.78

52 WEEK

3.48 - 41

Join Discuss about TGTX with like-minded investors

profile
@ivtrades-Chris #ivtrades
recently

$TGTX - Bullish option flow detected in TG Therapeutics (6.52 +0.11) with 3,724 calls trading (1.2x expected) and implied vol increasing almost 11 points to 129.55%. . The Put/Call Ratio is 0.27.

91 Replies 12 πŸ‘ 9 πŸ”₯

profile
@dros #droscrew
recently

Increasing unusual call volume: $FRSH $BDSI $SB $TAK $GSM $TCOM Increasing unusual put volume: $TIP $WEBR $TGTX $ITUB $MNMD $MCHI $ZI $EWG

87 Replies 14 πŸ‘ 12 πŸ”₯

profile
@Snowcow #droscrew
recently

$tgtx might be worth watching here

104 Replies 7 πŸ‘ 9 πŸ”₯

profile
@Snowcow #droscrew
recently

$tgtx nice move today

69 Replies 13 πŸ‘ 14 πŸ”₯

profile
@dros #droscrew
recently

TGTX looks a lot like the sector chartΒ 

90 Replies 11 πŸ‘ 7 πŸ”₯

profile
@bronco #droscrew
recently

@Snowcow You got me wanting this $TGTX, looking ready!

146 Replies 10 πŸ‘ 14 πŸ”₯

profile
@Snowcow #droscrew
recently

$tgtx looks interesting

123 Replies 7 πŸ‘ 15 πŸ”₯

Key Metrics

Market Cap

668.74 M

Beta

2.30

Avg. Volume

4.46 M

Shares Outstanding

144.44 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-01

Next Dividend Date

Company Information

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.

CEO: Michael Weiss

Website:

HQ: 2 Gansevoort St Fl 9 New York, 10014-1667 New York

Related News